Background: The relationship between serum hormone levels and adolescent acne is not fully clarified. Objective: To determine the relationship between levels of androstenedione, dehydroepiandrosterone sulfate (DHEA-S), testosterone, estradiol and 17α-hydroxyprogesterone (17-OHP) with adolescent acne in Northeast China. Methods: A transversal study included 242 acne cases and 188 controls. All data were analyzed using SPSS version 17.0. Results: Androstenedione and testosterone levels were significantly higher (p < 0.0001) in the cases than in the control group. In males, the difference in 17-OHP levels was statistically significant (p < 0.0001), as well as between mild and severe acne cases (p = 0.002). The estradiol level was significantly different (p < 0.0001) between cases and controls in females. Conclusion: Higher androstenedione and testosterone levels are significant risk factors in the occurrence of adolescent acne. A higher 17-OHP level aggravates the severity of male adolescent acne, while a higher estradiol level protects females against the onset of adolescent acne.

Webster GF: Acne vulgaris. BMJ 2002;325:475-479.
Cunliffe WJ: The sebaceous gland and acne - 40 years on. Dermatology 1998;196:9-15.
Bergfeld WF: The pathophysiology of acne vulgaris in children and adolescents. Part 1. Cutis 2004;74:92-97.
Gómez VM, Navarra AR, Lamarca M, et al: Ethinylestradiol/chlormadinone acetate for use in dermatological disorders. Am J Clin Dermatol 2011;12:13-19.
Joish VN, Boklage S, Lynen R, et al: Use of drospirenone/ethinyl estradiol (DRSP/EE) among women with acne reduces acne treatment-related resources. J Med Econ 2011;14:681-689.
Rademaker M, Garioch JJ, Simpson NB: Acne in schoolchildren: no longer a concern for dermatologists. Br Med J 1989;298:1217-1219.
Pearl A, Arroll B, Lello J, Birchall NM: The impact of acne: a study of adolescents' attitudes, perception and knowledge. NZ Med J 1998;1111:269-271.
Wei B, Pang Y, Zhu H, et al: The epidemiology of adolescent acne in North East China. J Eur Acad Dermatol Venereol 2010;24:953-957.
Hamilton JB: Male hormone substance: a prime factor in acne. J Clin Endocrinol 1941;1:570.
Lawrence DM, Katz M, Robinson TW, et al: Reduced sex hormone binding globulin and derived free testosterone levels in women with severe acne. Clin Endocrinol Oxf 1981;15:87-91.
Darley CR, Kirby JD, Besser GM, et al: Circulating testosterone, sex hormone binding globulin and prolactin in women with late onset or persistent acne vulgaris. Br J Dermatol 1982;106:517-522.
Gonzaga da Cunha M, Fonseca FLA, Machado CDAS: Androgenic hormone profile of adult women with acne. Dermatology 2013;226:167-171.
Ginsberg GS, Birnbaum MD, Rose LI: Androgen abnormalities in acne vulgaris. Acta Derm Venereol 1981;61:431-434.
Palatsi R, Reinilam M, Kivinen S: Pituitary function and DHEA-S in male acne and DHEA-S, prolactin and cortisol before and after oral contraceptive treatment in female acne. Acta Derm Venereol 1986;66:225-230.
Arora MK, Yadav A, Saini V: Role of hormones in acne vulgaris. Clin Biochem 2011;44:1035-1040.
Keller PJ, Fetz A, Schär A, et al: Treatment of acne and seborrhea using antiandrogens. Schweiz Med Wochenschr 1978;108:1640-1642.
Bachelot A, Chabbert-Buffet N, Salenave S, et al: Anti-androgen treatments. Ann Endocrinol 2010;71:19-24.
Zouboulis CC, Rabe T: Hormonal antiandrogens in acne treatment. J Dtsch Dermatol Ges 2010;8(suppl 1):S60-S74.
Placzek M, Arnold B, Schmidt H, et al: Elevated 17-hydroxyprogesterone serum values in male patients with acne. J Am Acad Dermatol 2005;53:955-958.
Marynick SP, Chakmakjian ZH, McCaffree DL, et al: Androgen excess in cystic acne. N Engl J Med 1983;308:981-986.
Ramsay B, Alaghband Zadeh J, Carter G, et al: Raised serum 11-deoxycortisol in men with persistent acne vulgaris. Clin Endocrinol Oxf 1995;43:305-310.
Trakakis E, Papadavid E, Dalamaga M, et al: Prevalence of non-classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency in Greek women with acne: a hospital-based cross-sectional study. J Eur Acad Dermatol Venereol 2013;27:1448-1451.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.